Crossmark

Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson’s disease

Crossref DOI link: https://doi.org/10.1186/s13041-019-0514-8

Published Online: 2019-10-30

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Stanojlovic, Milos https://orcid.org/0000-0001-5261-3712
Pallais, Jean Pierre

Lee, Michael K.

Kotz, Catherine M.
Funding

Funding for this research was provided by:

U.S. Department of Veterans Affairs (5I01RX000441-04)

Foundation for the National Institutes of Health (5R01DK100281-03)

Foundation for the National Institutes of Health (R01NS086074)

Foundation for the National Institutes of Health (R01NS092093)

Foundation for the National Institutes of Health (R01NS108686)

Foundation for the National Institutes of Health (R01AG062135)
License Information

Text and Data Mining valid from 2019-10-30

Version of Record valid from 2019-10-30
More Information

Article History

Received: 30 July 2019

Accepted: 18 October 2019

First Online: 30 October 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below